Developing COVID-19 Vaccines in Record Time, Part 4: Update on Vaccines
November 8, 2021
COVID-19 Vaccine Update Part 4 – Updates from vaccine developers regarding COVID-19 vaccines for children and adults.
This webinar, supported by the National Adult and Influenza Immunization Summit (NAIIS), featured updates from COVID-19 vaccine developers regarding COVID-19 vaccines for adults and children. This is the 4th in a series of webinars featuring vaccine manufacturers presenting their latest updates on COVID-19 vaccine research for specific populations, development, and rollout. We featured presentations from companies with currently available COVID-19 vaccines, and/or vaccine candidates in later clinical trial phases (Phase 2/3) as well vaccines in earlier phases of clinical development. We asked all companies to present updates on either: (1) published or other data plus timing of next phase of trials; (2) published Phase 2 data as well as a description and updates on the progress of Phase 3 trials; or (3) current vaccines and their roll out; availability of doses over the next few months; and/or other developments with regard to dosing or formulation that would be of interest to NAIIS partners.
After the presentations, there was a moderated discussion of scientific and implementation topics: understanding of the variants/mutations of SARS-CoV2 and the vaccines; thoughts about duration of immunity, impact of vaccination on transmission, and industry thoughts on potential changes in formulations as the SARS-CoV-2 viruses continue to evolve. Questions for the attendees were also taken.
This meeting was moderated by Phyllis Arthur, Vice President, Infectious Diseases & Emerging Science Policy, at BIO. We at the Summit are delighted and grateful for this opportunity to collaborate with BIO on this important discussion.
Phil Dormitzer MD, PhD
Vice President and Chief Strategy Officer, Viral Vaccines
(presentation not posted per presenter’s request)
- Moderna (slides)
James Mansi, PhD
Vice President of Medical Affairs-Americas
Video: Moderna: Update to the mRNA-1273 COVID-19 Vaccine Program
- Johnson & Johnson (slides)
Chime Nnadi , MD, PhD
Senior Director, US Vaccine Medical Affairs, Janssen Infectious Diseases & Vaccines
Video: J&J: COVID-19 Vaccine Update Webinar Series
- Novavax (slides)
Seth Toback, MD, FAAP
Vice President, Medical Affairs
Video: Novavax: NAIIS-Developing COVID-19 Vaccines in Record Time
- Sanofi Pasteur (slides)
Roman Chicz, PhD
Global Project Head, Recombinant COVID Vaccine
Video: Sanofi: BIO Panel: COVID-19 Vaccine Development Update
- Dynavax (slides)
Chief Medical Officer
Video: Dynavax: CpG 1018 in COVID-19 Vaccines